Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Alexion Pharmaceuticals up Big!

 (Image source: acquisitionsdaily.com)

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) are on a tear this morning after releasing fourth quarter earnings that exceed estimates by four cents. The biopharmaceutical company reported adjusted EPS of $0.83. Compared to a year ago, net product sales are up 38 percent. Sales were fueled by the blood disorder drug Soliris. According to Alexion, sales of Soliris were well above a billion for fiscal year 2013. The company is also working on treatment initiatives that use Soliris to help fight ultra-rare disorders. Investors are excited about Alexion’s R&D pipeline. Alexion also raised their 2014 earnings forecast above prevalent consensus. Shares are currently climbing 24 percent.